nafronyl has been researched along with Intermittent Claudication in 59 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 8.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "There is no consensus on the efficacy of physical training, smoking cessation, and pharmacological therapy (pentoxifylline or nafronyl oxalate) in the treatment of patients with intermittent claudication at Fontaine stage II of disease." | 8.80 | Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. ( Bernardi, E; Büller, HR; Girolami, A; Girolami, B; Hettiarachchi, R; Prandoni, P; Prins, MH; Ten Cate, JW, 1999) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 7.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| "To estimate the cost effectiveness of cilostazol (Pletal) compared to naftidrofuryl and pentoxifylline (Trental) in the treatment of intermittent claudication in the UK." | 7.73 | Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. ( Clegg, JP; Davie, AM; Guest, JF, 2005) |
| " According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication." | 5.26 | Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 4.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management." | 3.80 | Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. ( Harnan, S; Meng, Y; Michaels, J; O'Donnell, ME; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2014) |
| "To estimate the cost effectiveness of cilostazol (Pletal) compared to naftidrofuryl and pentoxifylline (Trental) in the treatment of intermittent claudication in the UK." | 3.73 | Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. ( Clegg, JP; Davie, AM; Guest, JF, 2005) |
| "Following an initial one month placebo run-in 235 patients, with stable IC for at least 3 months, were randomized to either naftidrofuryl (Praxilene), at a dosage of 200 mg three times daily, or matching placebo, for 6 months." | 2.70 | Naftidrofuryl in quality of life (NIQOL). A Belgian study. ( Clement, DL; D'Hooge, D; Lehert, P, 2001) |
| " Following an initial one month placebo run-in, patients were randomised to either naftidrofuryl, at a dosage of 200 mg three times daily, or matching placebo, for 6 months." | 2.69 | Naftidrofuryl can enhance the quality of life in patients with intermittent claudication. ( Brown, TM; Lehert, P; Poth, J; Spengel, F, 1999) |
| "A retrospective analysis was performed on all five published clinical trials in which naftidrofuryl was given at a dosage of 600 mg daily." | 2.67 | Naftidrofuryl in intermittent claudication: a retrospective analysis. ( Brown, TM; Comte, S; Gamand, S; Lehert, P, 1994) |
| "Authors and companies were approached for additional information and individual patient data." | 2.45 | Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. ( De Backer, T; Lehert, P; Van Bortel, L; Vander Stichele, R, 2009) |
| "Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated." | 2.45 | Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009) |
| "Intermittent claudication is a common disabling condition that affects approximately 5% to 15% of patients with atherosclerotic disease." | 2.41 | Can claudication be improved with medication? ( Conners, MS; Money, SR, 2002) |
| "Cilostazol has also been shown to improve the physical dimensions of quality of life." | 2.41 | New treatment options in intermittent claudication: the US experience. ( Hiatt, WR, 2001) |
| " According to our results, buflomedil is more effective and safe than naftidrofuryl in the treatment of patients with intermittent claudication." | 1.26 | Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication. ( Cerdeyra, C; Lucas, MA; Parano, JR; Rosas, G; Villa, JJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (28.81) | 18.7374 |
| 1990's | 15 (25.42) | 18.2507 |
| 2000's | 17 (28.81) | 29.6817 |
| 2010's | 9 (15.25) | 24.3611 |
| 2020's | 1 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bourrion, B | 1 |
| Hazard, A | 1 |
| Baltazard, H | 1 |
| Sebbag, P | 1 |
| Fournier, L | 1 |
| François, M | 1 |
| Melzer, J | 1 |
| Saller, R | 1 |
| Roset, PN | 1 |
| Stevens, JW | 3 |
| Simpson, E | 4 |
| Harnan, S | 4 |
| Squires, H | 4 |
| Meng, Y | 4 |
| Thomas, S | 4 |
| Michaels, J | 4 |
| Stansby, G | 4 |
| Hong, H | 1 |
| Mackey, WC | 1 |
| De Backer, T | 2 |
| Vander Stichele, R | 4 |
| Lehert, P | 11 |
| Van Bortel, L | 4 |
| Dobesh, PP | 1 |
| Stacy, ZA | 1 |
| Persson, EL | 1 |
| De Buyzere, M | 1 |
| De Backer, G | 1 |
| Stevens, J | 1 |
| Wong, R | 1 |
| de Backer, TL | 3 |
| O'Donnell, ME | 1 |
| Conners, MS | 1 |
| Money, SR | 1 |
| Boccalon, H | 3 |
| Mosnier, M | 1 |
| Landi, A | 1 |
| Guest, JF | 1 |
| Davie, AM | 1 |
| Clegg, JP | 1 |
| Goldsmith, DR | 1 |
| Wellington, K | 1 |
| Heidrich, H | 3 |
| Maass, U | 1 |
| Amberger, HG | 1 |
| Böhme, H | 1 |
| Diehm, C | 4 |
| Dimroth, H | 1 |
| Heinrich, F | 1 |
| Hirche, H | 2 |
| Mörl, H | 1 |
| Müller-Bühl, U | 1 |
| Clyne, CA | 1 |
| Galland, RB | 1 |
| Fox, MJ | 1 |
| Gustave, R | 1 |
| Jantet, GH | 1 |
| Jamieson, CW | 1 |
| Waters, KJ | 1 |
| Craxford, AD | 1 |
| Chamberlain, J | 1 |
| Rosas, G | 1 |
| Cerdeyra, C | 1 |
| Lucas, MA | 1 |
| Parano, JR | 1 |
| Villa, JJ | 1 |
| Moody, AP | 1 |
| al-Khaffaf, HS | 1 |
| Harris, PL | 1 |
| Charlesworth, D | 1 |
| Comte, S | 1 |
| Gamand, S | 4 |
| Brown, TM | 2 |
| Komarov, AL | 1 |
| Panchenko, EP | 1 |
| Eshkeeva, AR | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Karpov, IuA | 1 |
| Mouren, X | 2 |
| Caillard, P | 1 |
| Bensoussan, JJ | 1 |
| Massonneau, M | 1 |
| Stevens, WH | 1 |
| Pérez Encinas, M | 1 |
| Fernández, MA | 1 |
| Martín, ML | 1 |
| Calvo, MV | 1 |
| Gómez-Alonso, A | 1 |
| Dominguez-Gil, A | 1 |
| Lozano, F | 1 |
| Spengel, FA | 1 |
| Dietze, S | 1 |
| Girolami, B | 1 |
| Bernardi, E | 1 |
| Prins, MH | 1 |
| Ten Cate, JW | 1 |
| Hettiarachchi, R | 1 |
| Prandoni, P | 1 |
| Girolami, A | 1 |
| Büller, HR | 1 |
| Neill, R | 1 |
| Spengel, F | 2 |
| Poth, J | 1 |
| Vander Stichele, RH | 1 |
| Warie, HH | 1 |
| Bogaert, MG | 1 |
| Kieffer, E | 1 |
| Bahnini, A | 1 |
| Hiatt, WR | 1 |
| D'Hooge, D | 1 |
| Clement, DL | 1 |
| Doggrell, SA | 1 |
| Clément, D | 1 |
| Liard, F | 1 |
| Brown, T | 1 |
| Ruckley, CV | 1 |
| Callam, MJ | 1 |
| Ferrington, CM | 1 |
| Prescott, RJ | 1 |
| Kriessmann, A | 2 |
| Neiss, A | 2 |
| Lutilsky, L | 1 |
| Beermann, M | 1 |
| Kramann, B | 1 |
| Becker, HM | 1 |
| Elert, O | 1 |
| Häring, R | 1 |
| Maurer, PC | 1 |
| Raithel, D | 1 |
| Sperling, M | 1 |
| Stockmann, U | 1 |
| Storz, LW | 1 |
| Alanen, A | 1 |
| Kallio, T | 1 |
| Lehto, I | 1 |
| Wiernsperger, N | 1 |
| Adhoute, G | 2 |
| Andreassian, B | 1 |
| Cloarec, M | 1 |
| Di Maria, G | 1 |
| Lefebvre, O | 1 |
| Mondine, P | 1 |
| Plagnol, P | 1 |
| Pointel, JP | 1 |
| Quancard, X | 1 |
| Riphagen, FE | 1 |
| Depairon, M | 1 |
| Depresseux, JC | 1 |
| Petermans, J | 1 |
| Zicot, M | 1 |
| Weiss, T | 1 |
| Wilhelm, C | 1 |
| Hübsch-Müller, C | 2 |
| Hsu, E | 1 |
| Kühn, A | 1 |
| Strauss, R | 1 |
| Kübler, W | 1 |
| Taggart, I | 1 |
| Wishart, GC | 1 |
| Cuschieri, RJ | 1 |
| MacBain, GC | 1 |
| Ruckley, VC | 1 |
| Karnik, R | 2 |
| Valentin, A | 2 |
| Stöllberger, C | 2 |
| Slany, J | 2 |
| Bacourt, F | 1 |
| Barral, M | 1 |
| Cardon, JM | 1 |
| Chevalier, JM | 1 |
| Cuny, A | 1 |
| Gillet, M | 1 |
| Juhan, C | 1 |
| Leguay, G | 1 |
| Marion, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF[NCT00765050] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2009-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for nafronyl and Intermittent Claudication
| Article | Year |
|---|---|
[Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature].
Topics: Arterial Occlusive Diseases; Humans; Intermittent Claudication; Mobility Limitation; Nafronyl; Rando | 2020 |
[Clinical studies in peripheral arterial occlusive disease: update from the aspects of a meta-narrative review].
Topics: Arterial Occlusive Diseases; Cilostazol; Complementary Therapies; Humans; Intermittent Claudication; | 2013 |
The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Drug Approval; Endpoint Determination; Humans; Intermittent Cl | 2014 |
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data.
Topics: Female; Humans; Intermittent Claudication; Male; Middle Aged; Nafronyl; Pain; Randomized Controlled | 2009 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; | 2009 |
Silence of the limbs pharmacological symptomatic treatment of intermittent claudication.
Topics: Animals; Anticoagulants; Extremities; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interm | 2010 |
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Nicotinic Acids; Pen | 2011 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular D | 2012 |
Naftidrofuryl for intermittent claudication.
Topics: Administration, Oral; Humans; Intermittent Claudication; Nafronyl; Randomized Controlled Trials as T | 2012 |
Can claudication be improved with medication?
Topics: Carnitine; Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Platelet Aggrega | 2002 |
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematolog | 2004 |
Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
Topics: Humans; Intermittent Claudication; Nafronyl; Quality of Life; Randomized Controlled Trials as Topic; | 2005 |
Naftidrofuryl for intermittent claudication.
Topics: Administration, Oral; Humans; Intermittent Claudication; Nafronyl; Randomized Controlled Trials as T | 2008 |
[Peripheral arterial occlusions. Principles, possibilities and limits of conservative therapy].
Topics: Ancrod; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cardiomyopathies; Dextrans; Digitalis | 1981 |
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.
Topics: Clinical Trials as Topic; Exercise Therapy; Humans; Intermittent Claudication; Nafronyl; Pentoxifyll | 1999 |
Oral vasoactive medication in intermittent claudication: utile or futile?
Topics: Administration, Oral; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Pyrrolidines; Ran | 2000 |
New treatment options in intermittent claudication: the US experience.
Topics: Arginine; Carnitine; Cilostazol; Endothelial Growth Factors; Exercise Therapy; Humans; Intermittent | 2001 |
Pharmacotherapy of intermittent claudication.
Topics: Animals; Anticoagulants; Cardiotonic Agents; Carnitine; Cilostazol; Humans; Intermittent Claudicatio | 2001 |
The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
Topics: Adult; Aged; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent Claudica | 1990 |
24 trials available for nafronyl and Intermittent Claudication
| Article | Year |
|---|---|
[Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Intermittent Claudication; Male; Middle Aged; Nafron | 2001 |
[Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
Topics: Administration, Oral; Adult; Aged; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Bli | 1984 |
A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
Topics: Ankle; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Furans; Humans; Intermittent C | 1980 |
The effect of naftidrofuryl (Praxilene) on intermittent claudication.
Topics: Aged; Ankle; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Furans; Humans; | 1980 |
An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Intermittent Claudication; Male | 1994 |
Naftidrofuryl in intermittent claudication: a retrospective analysis.
Topics: Cardiovascular Diseases; Exercise; Female; Humans; Intermittent Claudication; Male; Middle Aged; Naf | 1994 |
The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease.
Topics: Aged; Area Under Curve; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudicatio | 1998 |
A statistical consideration of CLAU-S: a disease specific questionnaire for the assessment of quality of life in patients with intermittent claudication.
Topics: Humans; Intermittent Claudication; Nafronyl; Psychometrics; Quality of Life; Sick Role; Surveys and | 1998 |
Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise | 1999 |
A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Intermitt | 2001 |
Naftidrofuryl in quality of life (NIQOL). A Belgian study.
Topics: Adult; Aged; Aged, 80 and over; Belgium; Female; Humans; Intermittent Claudication; Male; Middle Age | 2001 |
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program.
Topics: Adult; Aged; Aged, 80 and over; Europe; Female; Follow-Up Studies; Humans; Intermittent Claudication | 2002 |
Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
Topics: Clinical Trials as Topic; Double-Blind Method; Furans; Humans; Intermittent Claudication; Nafronyl | 1978 |
[Drug therapy of intermittent claudication in the IIb stage of arterial occlusive disease].
Topics: Exercise Therapy; Furans; Humans; Infusions, Parenteral; Intermittent Claudication; Nafronyl | 1979 |
[Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study].
Topics: Arterial Occlusive Diseases; Double-Blind Method; Drug Evaluation; Femoral Artery; Furans; Humans; I | 1979 |
Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
Topics: Adult; Aged; Arteriosclerosis; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Huma | 1990 |
Assessment of flow and oxygen delivery to the lower extremity in arterial insufficiency: a PET-scan study comparison with other methods.
Topics: Double-Blind Method; Exercise Test; Humans; Intermittent Claudication; Leg; Middle Aged; Muscles; Na | 1991 |
[Does infusion therapy in trained patients with intermittent claudication have advantages?].
Topics: Alprostadil; Exercise Test; Humans; Infusions, Intravenous; Intermittent Claudication; Nafronyl | 1990 |
Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
Topics: Aged; Alprostadil; Combined Modality Therapy; Exercise Therapy; Female; Furans; Humans; Infusions, I | 1989 |
[Clinical effectiveness of naftidrofuryl in intermittent claudication].
Topics: Administration, Oral; Aged; Double-Blind Method; Female; Furans; Humans; Intermittent Claudication; | 1988 |
Effects of naftidrofuryl in patients with intermittent claudication.
Topics: Administration, Oral; Aged; Ankle; Blood Pressure; Brachial Artery; Clinical Trials as Topic; Double | 1988 |
[Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Furans; Humans; Intermittent Claudication; Ma | 1987 |
Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
Topics: Administration, Oral; Adult; Aged; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Doub | 1986 |
[Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
Topics: Arterial Occlusive Diseases; Cardiovascular Agents; Cinnarizine; Clinical Trials as Topic; Dihydroer | 1985 |
16 other studies available for nafronyl and Intermittent Claudication
| Article | Year |
|---|---|
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Topics: Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Peripheral Vascular Diseases; Tetrazole | 2013 |
Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Topics: Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Peripheral Vascular Diseases; Tetrazole | 2013 |
Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
Topics: Cilostazol; Cost-Benefit Analysis; Decision Support Techniques; Humans; Intermittent Claudication; M | 2014 |
[Current EMNID survey on peripheral arterial occlusive disease].
Topics: Arterial Occlusive Diseases; Evidence-Based Medicine; Germany; Guideline Adherence; Humans; Intermit | 2002 |
[Evidence-based therapy of intermittent claudication].
Topics: Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Evidence-Base | 2004 |
Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Topics: Adult; Cilostazol; Cost-Benefit Analysis; Humans; Intermittent Claudication; Nafronyl; Pentoxifyllin | 2005 |
Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
Topics: Butyrophenones; Double-Blind Method; Evaluation Studies as Topic; Furans; Humans; Intermittent Claud | 1981 |
[The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
Topics: Drug Evaluation; Female; Fibrinolysis; Hemostasis; Humans; Intermittent Claudication; Male; Middle A | 1996 |
Multicriteria decision analysis for determining drug therapy for intermittent claudication.
Topics: Decision Support Techniques; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Probabilit | 1998 |
A meta-analysis of the treatment of intermittent claudication.
Topics: Exercise Therapy; Humans; Intermittent Claudication; Meta-Analysis as Topic; Nafronyl; Pentoxifyllin | 1999 |
[Intermittent claudication. Walking plus vasoactive drug treatment].
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Me | 2001 |
Naftidrofuryl (Praxilene) in peripheral vascular disease.
Topics: Animals; Furans; Humans; Intermittent Claudication; Ischemia; Leg; Male; Mice; Middle Aged; Nafronyl | 1979 |
The effect of naftidrofuryl on red blood cell aggregation detected in vitro with ultrasound.
Topics: Aged; Case-Control Studies; Erythrocyte Aggregation; Female; Humans; In Vitro Techniques; Intermitte | 1990 |
[Possibilities and limits of physical training therapy of intermittent claudication patients with simultaneous drug therapy].
Topics: Alprostadil; Combined Modality Therapy; Exercise; Follow-Up Studies; Humans; Intermittent Claudicati | 1991 |
Effect of intravenous naftidrofuryl on transcutaneous oxygen pressure in severe peripheral vascular disease.
Topics: Aged; Blood Gas Monitoring, Transcutaneous; Female; Furans; Humans; Intermittent Claudication; Leg; | 1989 |
Claudication.
Topics: Aged; Aorta, Abdominal; Endarterectomy; Femoral Artery; Humans; Intermittent Claudication; Nafronyl; | 1986 |